From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
作者信息
Rangachari Deepa, Costa Daniel B
机构信息
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
出版信息
J Clin Oncol. 2019 Oct 1;37(28):2511-2513. doi: 10.1200/JCO.19.01207. Epub 2019 Jun 2.
Abstract
摘要
相似文献
1
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.从希望到现实：免疫检查点抑制剂为晚期肺癌带来持久总生存期
J Clin Oncol. 2019 Oct 1;37(28):2511-2513. doi: 10.1200/JCO.19.01207. Epub 2019 Jun 2.
2
Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.非小细胞肺癌免疫检查点阻断剂长期疗效预测的进展
Immunotherapy. 2019 Aug;11(12):993-1003. doi: 10.2217/imt-2019-0107. Epub 2019 Jul 19.
3
Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.免疫疗法药物可提高鳞状非小细胞肺癌患者的生存率。
Cancer. 2015 Oct 15;121(20):3562-3. doi: 10.1002/cncr.29700.
4
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.晚期非小细胞肺癌患者的循环肿瘤细胞与对检查点抑制剂的肿瘤反应更差有关。
J Immunother Cancer. 2019 Jul 10;7(1):173. doi: 10.1186/s40425-019-0649-2.
5
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.免疫检查点阻断与肺肉瘤样癌的持久反应相关。
Clin Lung Cancer. 2019 May;20(3):e242-e246. doi: 10.1016/j.cllc.2018.12.013. Epub 2018 Dec 24.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.TP53 突变与晚期非小细胞肺癌免疫检查点抑制剂治疗应答和生存延长的相关性。
Lung Cancer. 2019 Jun;132:65-71. doi: 10.1016/j.lungcan.2019.04.005. Epub 2019 Apr 8.
8
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.抗生素与中国晚期非小细胞肺癌患者抗 PD-1/PD-L1 治疗疗效减弱相关。
Lung Cancer. 2019 Apr;130:10-17. doi: 10.1016/j.lungcan.2019.01.017. Epub 2019 Jan 31.
9
First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.一线检查点抑制剂治疗野生型晚期非小细胞肺癌：一项两两比较和网络荟萃分析。
Immunotherapy. 2019 Mar;11(4):311-320. doi: 10.2217/imt-2018-0107.
10
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.免疫相关不良反应与免疫检查点抑制剂在非小细胞肺癌中的疗效相关性。
Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11.
引用本文的文献
1
Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）中 PD-1/PD-L1 表达的临床病理研究，重点是大 B 细胞 Richter 转化。
Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4243-4252. doi: 10.31557/APJCP.2023.24.12.4243.
2
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.免疫检查点抑制剂在携带有 NTRK 家族突变的非小细胞肺癌中的疗效。
BMC Pulm Med. 2023 Nov 29;23(1):482. doi: 10.1186/s12890-023-02707-x.
3
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.中国恶性胸膜间皮瘤诊断与治疗专家共识。
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
4
Prognostic Value and Immunological Role of P4HA3 in Colon Adenocarcinoma.P4HA3在结肠腺癌中的预后价值及免疫作用
Int J Gen Med. 2023 May 23;16:1953-1971. doi: 10.2147/IJGM.S407068. eCollection 2023.
5
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy.免疫治疗患者中性粒细胞与淋巴细胞比值早期变化与生存的关系
J Clin Med. 2022 Aug 3;11(15):4523. doi: 10.3390/jcm11154523.
6
Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.血清生物标志物在 PD-1 抑制剂治疗 IV 期非小细胞肺癌中的临床意义：LIPI 评分、NLR、dNLR、LMR 和 PAB。
Dis Markers. 2022 Jul 30;2022:7137357. doi: 10.1155/2022/7137357. eCollection 2022.
7
Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology.中性粒细胞胞外诱捕网在心血管肿瘤学中的潜在作用。
Int J Mol Sci. 2022 Mar 25;23(7):3573. doi: 10.3390/ijms23073573.
8
Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc.长链非编码 RNA AFAP1-AS1 通过与 SNIP1 相互作用来上调 c-Myc，从而促进肺癌细胞的迁移和侵袭。
Signal Transduct Target Ther. 2021 Jun 25;6(1):240. doi: 10.1038/s41392-021-00562-y.
9
Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer.血清代谢物生物标志物可预测非小细胞肺癌对PD-1阻断疗法的反应
Front Mol Biosci. 2021 May 21;8:678753. doi: 10.3389/fmolb.2021.678753. eCollection 2021.
10
The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.
Cancer Cytopathol. 2021 Mar;129(3):179-181. doi: 10.1002/cncy.22334. Epub 2020 Aug 5.
本文引用的文献
1
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.帕博利珠单抗治疗晚期非小细胞肺癌患者的 5 年总生存结果：来自 I 期 KEYNOTE-001 研究的结果。
J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.
2
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.克唑替尼治疗 ROS1 重排的晚期非小细胞肺癌（NSCLC）：PROFILE 1001 研究的更新结果，包括总生存期。
Ann Oncol. 2019 Jul 1;30(7):1121-1126. doi: 10.1093/annonc/mdz131.
3
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
4
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.不断发展的免疫检查点抑制剂治疗生物标志物。
Nat Rev Cancer. 2019 Mar;19(3):133-150. doi: 10.1038/s41568-019-0116-x.
5
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.IV 期 ALK 重排非小细胞肺癌的自然病史及与总生存相关的因素。
J Thorac Oncol. 2019 Apr;14(4):691-700. doi: 10.1016/j.jtho.2018.12.014. Epub 2018 Dec 30.
7
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
8
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
9
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
10
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
Zotero 插件